Lots of drama ensues from a 46 second zoom meeting!
Default Judgment Sought as Rhelion Life Sciences Corp. Misses Deadline; Filament Health Corp. Registered Address Changed to a Two-Bedroom Residential Apartment
Burnaby, British Columbia, September 8, 2026 – Rhelion Life Sciences Corp. (CSE: RHEL) (FSE: 4YX0) (OTCQB: TRUFF) (“Rhelion”) is a Defendant in a suit brought by the former Intellectual Property Director of Filament Health Corp. (“Filament”). Taran Grey had occupied the role at Filament for more than six (6) years. On April 30, 2026, Rhelion completed its acquisition of Filament. Claims in suit include, but are not limited to: Breach of Contract; Tortious Inducement of Breach of Contract; Wrongful Dismissal; and, Unlawful Interference with Economic Relations.
On June 16, 2026, six (6) weeks following the acquisition, Rhelion’s CEO, Todd Shapiro, terminated Mr. Grey’s employment during a Zoom meeting forty-six (46) seconds in duration. Mr. Shapiro is alleged to have immediately filled that career vacancy with Rhelion’s “Strategic Advisor”, Sarah Haskes. By Mr. Shapiro’s admission, Rhelion had only one other employee aside from Mr. Shapiro and Ms. Haskes: Mr. Shapiro’s personal assistant.
On July 7, 2026, Rhelion received a document request (the “Request”). The document request concerned the particulars, if any, of contractual obligations related to the acquisition of Filament; namely, the forbearance of termination without cause of Filament employees following acquisition (the “Forbearance Agreement”) in general; and more specifically, termination without cause whereby the role of the terminated Filament employee is immediately filled by a Rhelion employee.
On August 6th, 2026, Rhelion was served, and has acknowledged receipt of, all pertinent court documents related to the lawsuit. To date, no response has been entered by Rhelion. As a direct result, a Default Judgment against Rhelion can be sought.
Todd Shapiro and Sarah Haskes currently comprise the entirety of the Filament Board of Directors as all previous Directors have been removed. In addition, it is alleged that the registered office address of Filament Health Corp., referred to as the “Vancouver head office” by the British Columbia Securities Commission in an order dated August 19, 2026, was changed to a 1000 square foot, two-bedroom residential apartment associated with an individual not registered as an attorney in good standing with the Law Society of British Columbia. Filament’s federally licensed production facility and management offices remain on Wayburne Drive in Burnaby, British Columbia.
“It is important that those in the tech start-up ecosystem can trust that contractual obligations will be honoured following an acquisition or other liquidity event,” said Taran Grey. “Although filing suit was costly, the expense provides a new sense of security to existing Filament employees that the Rhelion Board of Directors will ensure contracts, be they employment or commercial, can be relied upon
